Gold Sponsor
WuXi Biologics
WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2022, WuXi Biologics is supporting 588 integrated client projects, including 17 in commercial manufacturing.
Associated Experts
Job Title: Vice President, Formulation, Fill and Finish
Job Title: Director of Cell Line Development and Protein Sciences
Job Title: Vice President, Cell Culture Process Development
Job Title: Vice President
Job Title: CEO, WuXi XDC, a WuXi Biologics subsidiary.
Job Title: Vice President, Process and Analytical Development
Job Title: Senior Director, Regulatory Affairs
Job Title: Head of Biologics Conjugation Development
Job Title: Vice President of CMC Management
Job Title: Director of Corporate Development
Associated Content
Advanced Biomanufacturing Platforms to Increase Productivity and Drive Down Cost of Goods via WuXiUITM Intensified Fed-batch and WuXiUPTM Continuous Process Strategies
Continuous manufacturing offers benefits such as reduced manufacturing scale, equipment costs, and facility footprint, making it an attractive option for challenging-to-produce proteins. However, imagine applying optimized continuous process strategies for the production of monoclonal antibodies, ... Continued
Assessing Developability in the Antibody Discovery Stage is A Key to Success
We recently sat down with Dr. George Wang, Vice President of Discovery and Preclinical Services at WuXi Biologics to discuss the importance of looking at developability of an antibody early in the drug discovery process. ... Continued
Streamline the ADC Path to the Clinic with One-stop Drug Development and Critical Technology Advancements
In this podcast, I talked with Dr. Jimmy Li, CEO of WuXi XDC, a WuXi Biologics subsidiary. We discussed the reasons for the formation of WuXi XDC, which was established via a joint venture between WuXi Biologics and WuXi STA, a WuXi AppTec subsidiary, and how one-stop drug development organizations greatly streamline a pathway to the clinic. He also shares new technologies available to make the development of Antibody Drug Conjugates (ADCs) more efficient and effective. ...Continued
The benefits of using a single-source for discovery, development and GMP manufacture of antibody drug conjugates and other novel bioconjugates
In this podcast, I talked with Dr. Jimmy Li, CEO of WuXi XDC, a WuXi Biologics subsidiary. We discussed the reasons for the formation of WuXi XDC, which was established via a joint venture between WuXi Biologics and WuXi STA, a WuXi AppTec subsidiary, and how this company provides a true single-source for the discovery, development, and GMP manufacture of antibody drug conjugates and other novel bioconjugates with their highly efficient one-stop drug development platform....Continued
Applications and Impact of CRISPR/CAS9 in Bioprocessing
Experts from Wuxi Biologics talk about one of the great technological advancements of the last decade, CRISPR/Cas9 technology. We discussed the technology’s potential and in particular its possibilities in the discovery and development of biopharmaceuticals. We also conducted a deep dive on its potential impact on bioprocessing and biomanufacturing....Continued
Reducing Fill Risk in Drug Product Manufacture Utilizing New State-of-the-Art Systems and Platforms
In this podcast we talked with DQ Wang, PhD, and Vice President, Formulation, Fill and Finish of WuXi Biologics about their DP4 multi-product fill & finish facility featuring the Vanrx SA25 robotic, gloveless, isolator-based filling system. The system significantly reduces drug product fill risk and provides greater aseptic assurance....Continued
The Challenge of Staying Current with Regulatory Changes – How one company is providing a solution
In this podcast, we talked with Ken Chen, MBA, Senior Director, Regulatory Affairs, WuXi Biologics about staying current with regulatory changes. We discussed how WuXi Biologics recently began publishing a quarterly summary of regulatory updates on new or revised guidance documents from the various global regulatory agencies and how this is a valuable resource for anyone in the biological drug development arena....Continued
Antibody Drug Conjugate (ADC) Development and Manufacturing Challenges and Solutions
In this podcast, we interviewed Dr. J.J. Luo, Executive Director and Dr. Lily Yin, Head of Biologics Conjugation Development, at WuXi Biologics about the state of the ADC marketplace and the challenges in developing antibody drug conjugates. We then dove into reasons behind why they built a dedicated manufacturing facility for ADCs and other bioconjugates and how a single-source development platform can benefit bioconjugate drug development efforts....Continued
New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties and Manufacturability
This year’s Next Generation Protein Therapeutics & Bioconjugates™ Summit held in San Francisco provided an in-depth look at the latest developments in next-generation protein therapeutic discovery and manufacturing. One talk that I found of particular ... Continued
Biologic Products DNA to IND Timeline in 9 Months – Yes it can be done!
The ability to rapidly develop biologic products from conception to human clinical trials is an increasingly important aspect of controlling drug development costs and in expediting the drug’s pathway to one day provide critical treatments. ... Continued
Is Continuous Biomanufacturing a Good Fit for Your Process? – Continuous Biomanufacturing Implementation – Frequently Asked Questions
We recently finished our Ask the Expert discussion, “Ask the Expert – Implementation of Continuous Manufacturing Strategies for Protein Therapeutics.” During this Ask the Expert session, we covered several common questions related to continuous biomanufacturing, ... Continued
Scale-Out Biomanufacturing – A Paradigm Change to Scale Up
In biomanufacturing, a production scale change is required to either meet the market growth demand or when a product moves from clinical to commercial manufacturing. How that volume is increased depends on whether a scale ... Continued
Implementation of Continuous Manufacturing Strategies for Protein Therapeutics
Answers by: Hang Zhou, Ph.D., Director of Cell Culture Process Development, WuXi Biologics & Sherry Gu, Ph.D, Vice President of CMC Management, WuXi Biologics Introduction There continues to be growing interest in continuous processing of biological therapeutics with the primary ... Continued